Advertisement

Table of Contents

In the Spotlight

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures
    Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia
    Hiroshi Ureshino, Takero Shindo, Hiroyoshi Nishikawa, Nobukazu Watanabe, Eri Watanabe, Natsuko Satoh, Kazutaka Kitaura, Hiroaki Kitamura, Kazuko Doi, Kotaro Nagase, Hiromi Kimura, Makoto Samukawa, Susumu Kusunoki, Masaharu Miyahara, Tadasu Shin-I, Ryuji Suzuki, Shimon Sakaguchi and Shinya Kimura
    Cancer Immunol Res August 1 2016 4 (8) 644-649; DOI:10.1158/2326-6066.CIR-15-0303

    Anti-CCR4 treatment of ATL destroys leukemic and normal Tregs, which can lead to autoimmunity. Only leukemic Tregs expressed CADM1, distinguishing the two populations. Treg depletion was associated with autoimmunity and Treg reemergence with relapse of ATL.

Priority Brief

  • Priority Brief | AuthorChoice
    Interferon-γ Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade
    Michael J. McNamara, Ian Hilgart-Martiszus, Diego M. Barragan Echenique, Stefanie N. Linch, Melissa J. Kasiewicz and William L. Redmond
    Cancer Immunol Res August 1 2016 4 (8) 650-657; DOI:10.1158/2326-6066.CIR-16-0022

    PD-1/CTLA-4 dual blockade has shown substantial promise against refractory tumors in some patients. Biomarkers were sought to identify patients early in treatment who are responding positively. Strong production of IFNγ shortly after treatment commenced significantly correlated with survival.

Research Articles

  • Research Articles
    A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration
    Reona Sakemura, Seitaro Terakura, Keisuke Watanabe, Jakrawadee Julamanee, Erina Takagi, Kotaro Miyao, Daisuke Koyama, Tatsunori Goto, Ryo Hanajiri, Tetsuya Nishida, Makoto Murata and Hitoshi Kiyoi
    Cancer Immunol Res August 1 2016 4 (8) 658-668; DOI:10.1158/2326-6066.CIR-16-0043

    On-target/off-tumor effects can be problematic if the antigen target for CAR T-cell therapy is also expressed on normal tissue. An inducible CAR expression strategy was used that controlled CAR expression and shows promise in discriminating between tumor and B-cell expression of CD19.

  • Research Articles
    Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens
    Todd D. Prickett, Jessica S. Crystal, Cyrille J. Cohen, Anna Pasetto, Maria R. Parkhurst, Jared J. Gartner, Xin Yao, Rong Wang, Alena Gros, Yong F. Li, Mona El-Gamil, Kasia Trebska-McGowan, Steven A. Rosenberg and Paul F. Robbins
    Cancer Immunol Res August 1 2016 4 (8) 669-678; DOI:10.1158/2326-6066.CIR-15-0215

    On-target/off-tumor effects can be problematic if the antigen target for CAR T-cell therapy is also expressed on normal tissue. An inducible CAR expression strategy was used that controlled CAR expression and shows promise in discriminating between tumor and B-cell expression of CD19.

  • Research Articles
    Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes
    Vishwajith Sridharan, Evisa Gjini, Xiaoyun Liao, Nicole G. Chau, Robert I. Haddad, Mariano Severgnini, Peter Hammerman, Adel El-Naggar, Gordon J. Freeman, F. Stephen Hodi, Scott J. Rodig, Glenn Dranoff and Jonathan D. Schoenfeld
    Cancer Immunol Res August 1 2016 4 (8) 679-687; DOI:10.1158/2326-6066.CIR-16-0031

    PD-1 ligand expression and T-cell infiltration may predict responsiveness to PD-1 pathway inhibitors. ACC tumors expressed PD-L2 and the Wnt and PI3K pathways but had little immune infiltration. Chemoradiotherapy promoted antitumor responses, suggesting potential synergies with PD-1 blockade.

  • Research Articles
    HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment
    Maya Zigler, Alexei Shir, Salim Joubran, Anna Sagalov, Shoshana Klein, Nufar Edinger, Jeffrey Lau, Shang-Fan Yu, Gabriel Mizraji, Anat Globerson Levin, Mark X. Sliwkowski and Alexander Levitzki
    Cancer Immunol Res August 1 2016 4 (8) 688-697; DOI:10.1158/2326-6066.CIR-15-0203

    HER2 is overexpressed in many breast tumors. A therapy was developed that targeted pIC (a TLR3 ligand) to HER2-positive tumors. Tumor growth was significantly inhibited, and antitumor immunity was activated via multiple signaling pathways.

  • Research Articles
    Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells
    Rebekah L. Browning, William H. Byrd, Nikhil Gupta, Jeffrey Jones, Xiaokui Mo, Erin Hertlein, Lianbo Yu, Natarajan Muthusamy and John C. Byrd
    Cancer Immunol Res August 1 2016 4 (8) 698-707; DOI:10.1158/2326-6066.CIR-15-0291

    Lenalidomide is a potential therapy for patients with CLL. It induces IL21 production by T cells while increasing IL21 receptors on CLL B cells, with concomitant cytotoxicity to CLL B cells, operating through multiple mechanisms.

  • Research Articles
    Cross-talk between 4-1BB and TLR1–TLR2 Signaling in CD8+ T Cells Regulates TLR2′s Costimulatory Effects
    Ann Mary Joseph, Ratika Srivastava, Jovanny Zabaleta and Eduardo Davila
    Cancer Immunol Res August 1 2016 4 (8) 708-716; DOI:10.1158/2326-6066.CIR-15-0173

    The mechanisms underlying the costimulatory effects of TLR2 engagement on T cells are poorly understood. Costimulatory TLR1–TLR2 signaling in CD8+ T cells was found to be largely mediated by 4-1BB and contributes to mounting an antitumor immune response.

Back to top
Cancer Immunology Research: 4 (8)
August 2016
Volume 4, Issue 8

Sign up for alerts

Jump to

Advertisement